Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2018

View Archived Issues

Cleaning up synuclein

Crystal structure of Pseudomonas exotoxins and human 14-3-3 protein identifies a new target

ASM opens BBB in aging

Preclinical results presented for novel 6-amino-6-deoxy paramylon for the treatment of obesity

Novel anti-inflammatory CXCL12 neutraligand with improved characteristics discovered

Nilvadipine does not demonstrate efficacy in patients with mild to moderate Alzheimer's disease

Novel Janssen hepatitis B virus capsid assembly modulators possess potent antiviral activity

Hemispherx and Roswell Park enter clinical trial agreement to study Ampligen

U.S. DoD funding phase II combination study of TPIV-110 in breast cancer

Helix BioPharma, Moffitt Cancer Center expand collaboration

The nitty gritty: Drilling down into sepsis shows routes to treatment

Urinary exosomal CCL-21 mRNA as marker of histological injury and renal function deterioration in DN

PF-06939926 induces a greater amelioration of DMD pathology when administered at a younger age

GS-6207 shows long-acting nonclinical pharmacokinetic profile

R-DMDdel52, a new rat model of Duchenne muscular dystrophy, developed

Hypermethylation of miR-145-5p drives laryngeal squamous cell carcinoma invasion and metastasis

Chinese researchers patent adenosine A2A receptor antagonists

Gedeon Richter presents GABA-B receptor PAMs

New phase II/III trial in Brazil studies meningococcus C vaccine MenCC-Bio

Genentech and Roche identify MAP4K1 inhibitors

Cognition Therapeutics begins phase II trial of CT-1812 in mild to moderate Alzheimer's disease

Cardio Therapeutics patent describes PCSK9 inhibitors

Galera initiates phase III study of GC-4419 to reduce radiation-induced oral mucositis

Athenex discloses CRAC modulators as IL-2 production inhibitors

Perjeta approved in Japan for neoadjuvant and adjuvant use in HER2-positive early breast cancer

ASSESS trial demonstrates superior efficacy of Gilenya over Copaxone in relapsing-remitting MS

Ritter presents additional phase IIb data on RP-G28 for treatment of lactose intolerance

Stelara induces clinical remission and response in moderate to severe ulcerative colitis

Pharmaxis reports phase I data for first LOXL2 inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...